Gardasil
Generic name: human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
Treatment for: Human Papillomavirus Prophylaxis
Biologics License Application for Gardasil, Merck's Investigational Cervical Cancer Vaccine, Is On Track
WHITEHOUSE STATION, N.J., February 2, 2006 -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) Biologics License Application (BLA) for Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine) is on track and pending acceptance. Merck delivered the completed file to the FDA on December 1. Following the submission, the FDA informed Merck that the submission date is officially December 8. Within 60 days following official submission, the FDA will determine whether it will accept for review Merck's application as submitted.
Source: Merck & Co., Inc.
Posted: February 2006
Related articles
- FDA: Gardasil Approved to Prevent Anal Cancer - December 22, 2010
- FDA Approves Gardasil for Use in Boys and Young Men - October 16, 2009
- FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers - September 15, 2008
- FDA Approves Gardasil for Prevention of Cervical Cancer other HPV-related Diseases - June 8, 2006
- FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of Gardasil - May 18, 2006
- Gardasil, Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug Administration - February 7, 2006
- Merck Submits Biologics License Application to FDA for Gardasil, the Company's Investigational Vaccine for Cervical Cancer - December 5, 2005
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
